Filing Details
- Accession Number:
- 0001209191-23-022400
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-04-03 19:26:43
- Reporting Period:
- 2023-03-30
- Accepted Time:
- 2023-04-03 19:26:43
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1607678 | Viking Therapeutics Inc. | VKTX | Pharmaceutical Preparations (2834) | 461073877 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1614578 | Brian Lian | C/O Viking Therapeutics, Inc. 9920 Pacific Heights Blvd, Suite 350 San Diego CA 92121 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.00001 Per Share | Acquisiton | 2023-03-30 | 115,852 | $1.23 | 2,388,815 | No | 4 | M | Direct | |
Common Stock, Par Value $0.00001 Per Share | Acquisiton | 2023-03-30 | 19,530 | $9.49 | 2,408,345 | No | 4 | M | Direct | |
Common Stock, Par Value $0.00001 Per Share | Disposition | 2023-03-30 | 88,000 | $16.95 | 2,320,345 | No | 4 | S | Direct | |
Common Stock, Par Value $0.00001 Per Share | Disposition | 2023-03-30 | 65,382 | $17.45 | 2,254,963 | No | 4 | S | Direct | |
Common Stock, Par Value $0.00001 Per Share | Acquisiton | 2023-03-31 | 67,970 | $9.49 | 2,322,933 | No | 4 | M | Direct | |
Common Stock, Par Value $0.00001 Per Share | Disposition | 2023-03-31 | 67,970 | $17.45 | 2,254,963 | No | 4 | S | Direct | |
Common Stock, Par Value $0.00001 Per Share | Disposition | 2023-04-03 | 22,000 | $17.85 | 2,232,963 | No | 4 | S | Direct | |
Common Stock, Par Value $0.00001 Per Share | Acquisiton | 2023-04-03 | 300,000 | $0.00 | 2,532,963 | No | 4 | A | Direct | |
Common Stock, Par Value $0.00001 Per Share | Disposition | 2023-04-03 | 200,000 | $17.57 | 2,332,963 | No | 4 | F | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | A | Direct | |
No | 4 | F | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2023-03-30 | 115,852 | $0.00 | 115,852 | $1.23 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2023-03-30 | 19,530 | $0.00 | 19,530 | $9.49 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2023-03-31 | 67,970 | $0.00 | 67,970 | $9.49 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
134,148 | 2018-01-05 | 2027-01-05 | No | 4 | M | Direct |
67,970 | 2016-05-04 | 2025-05-04 | No | 4 | M | Direct |
0 | 2016-05-04 | 2025-05-04 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person
- The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2022, 66.67% of which vested on April 3, 2023 upon the achievement of two non-financial performance goals.
- These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units.
- 25% of the shares subject to the option vested on each one year anniversary of the grant date.
- 25% of the shares subject to the option vested upon grant and 25% of the shares subject to the option vested on each one year anniversary of the grant date.